Childhood hepatocellular carcinoma: A clinicopathological study of 12 cases with special reference to EpCAM

Histopathology

Volumn 64, Issue 5, 2014, Pages 671-682

  Zen, Yoh ^a   Vara, Roshni ^b   Portmann, Bernard ^a   Hadzic, Nedim ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Bile salt export transporter; Biliary atresia; Epithelial cell adhesion molecule; Hepatoblastoma; Hepatocellular carcinoma; Progressive intrahepatic cholestasis; Stem cell; Tyrosinaemia

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; ABC TRANSPORTER; ABCB11 PROTEIN, HUMAN; CELL ADHESION MOLECULE; EPCAM PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BILE DUCT ATRESIA; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; FEMALE; HEPATOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TOTAL PARENTERAL NUTRITION; TYROSINEMIA; AGE; CARCINOMA, HEPATOCELLULAR; CASE REPORT; COMPLICATION; DEFICIENCY; LIVER NEOPLASMS; METABOLISM; PATHOLOGY; PRESCHOOL CHILD;

ADULT; AGE FACTORS; ANTIGENS, NEOPLASM; ATP-BINDING CASSETTE TRANSPORTERS; BILIARY ATRESIA; CARCINOMA, HEPATOCELLULAR; CELL ADHESION MOLECULES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; LIVER NEOPLASMS; MALE; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; TYROSINEMIAS;

EID: 84896130679     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12312     Document Type: Article

References (29)

1. Theise ND, Curado MP, Franceschi F et al. Hepatocellular carcinoma. In Bosman FT, Carneiro F, Hruban RH, Theise ND eds. World Health Organization classification of tumours. Pathology and genetics of tumours of the digestive system. Lyon: IARC Press, 2010; 205-216.
2. Liu S, Chan KW, Wang B, Qiao L. Fibrolamellar hepatocellular carcinoma. Am. J. Gastroenterol. 2009; 104; 2617-2624.
3. Ward SC, Huang J, Tickoo SK, Thung SN, Ladanyi M, Klimstra DS. Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation. Mod. Pathol. 2010; 23; 1180-1190.
4. Abdul-Al HM, Wang G, Makhlouf HR, Goodman ZD. Fibrolamellar hepatocellular carcinoma: an immunohistochemical comparison with conventional hepatocellular carcinoma. Int. J. Surg. Pathol. 2010; 18; 313-318.
5. Hadzic N, Finegold MJ. Liver neoplasia in children. Clin. Liver Dis. 2011; 15; 443-462.
6. Cheah PL, Looi LM, Lin HP, Yap SF. Childhood primary hepatocellular carcinoma and hepatitis B virus infection. Cancer 1990; 65; 174-176.
7. Kim H, Lee MJ, Kim MR et al. Expression of cyclin D1, cyclin E, cdk4 and loss of heterozygosity of 8p, 13q, 17p in hepatocellular carcinoma: comparison study of childhood and adult hepatocellular carcinoma. Liver 2000; 20; 173-178.
8. Mieles LA, Esquivel CO, Van Thiel DH et al. Liver transplantation for tyrosinemia. A review of 10 cases from the University of Pittsburgh. Dig. Dis. Sci. 1990; 35; 153-157.
9. Knisely AS, Strautnieks SS, Meier Y et al. Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency. Hepatology 2006; 44; 478-486.
10. Yamashita T, Ji J, Budhu A et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009; 136; 1012-1024.
11. Zen C, Zen Y, Mitry RR et al. Mixed phenotype hepatocellular carcinoma after transarterial chemoembolization and liver transplantation. Liver Transpl. 2011; 17; 943-954.
12. Bae JS, Noh SJ, Jang KY et al. Expression and role of epithelial cell adhesion molecule in dysplastic nodule and hepatocellular carcinoma. Int. J. Oncol. 2012; 41; 2150-2158.
13. Yamashita T, Forgues M, Wang W et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 2008; 68; 1451-1461.
14. Kimura O, Takahashi T, Ishii N et al. Characterization of the epithelial cell adhesion molecule (EpCAM)+ cell population in hepatocellular carcinoma cell lines. Cancer Sci. 2010; 101; 2145-2155.
15. Theise ND, Park YN, Curado MP et al. Hepatocellular carcinoma. In Bosman FT, Carneiro F, Hruban RH, Theise ND eds. World Health Organization classification of tumours of the digestive system. Lyon: IARC Press, 2010; 205-216.
16. International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009; 49; 658-664.
17. Ruck P, Wichert G, Handgretinger R, Kaiserling E. Ep-CAM in malignant liver tumours. J. Pathol. 2000; 191; 102-103.
18. Jimenez-Rivera C, Jolin-Dahel KS, Fortinsky KJ, Gozdyra P, Benchimol EI. International incidence and outcomes of biliary atresia. J. Pediatr. Gastroenterol. Nutr. 2013; 56; 344-354.
19. Scott CR. The genetic tyrosinemias. Am. J. Med. Genet. C Semin. Med. Genet. 2006; 142C; 121-126.
20. Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. Progressive familial intrahepatic cholestasis. Orphanet J. Rare Dis. 2009; 4; 1.
21. Hadžić N, Quaglia A, Portmann B et al. Hepatocellular carcinoma in biliary atresia: King's College Hospital experience. J. Pediatr. 2011; 159; 617-622.
22. Weinberg AG, Mize CE, Worthen HG. The occurrence of hepatoma in the chronic form of hereditary tyrosinemia. J. Pediatr. 1976; 88; 434-438.
23. Jorquera R, Tanguay RM. Fumarylacetoacetate, the metabolite accumulating in hereditary tyrosinemia, activates the ERK pathway and induces mitotic abnormalities and genomic instability. Hum. Mol. Genet. 2001; 10; 1741-1752.
24. Orejuela D, Jorquera R, Bergeron A, Finegold MJ, Tanguay RM. Hepatic stress in hereditary tyrosinemia type 1 (HT1) activates the AKT survival pathway in the fah-/- knockout mice model. J. Hepatol. 2008; 48; 308-317.
25. Hirschmann-Jax C, Foster AE, Wulf GG et al. A distinct 'side population' of cells with high drug efflux capacity in human tumor cells. Proc. Natl Acad. Sci. USA 2004; 101; 14228-14233.
26. Yamashita T, Budhu A, Forgues M et al. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res. 2007; 67; 10831-10839.
27. de Boer CJ, van Krieken JH, Janssen-van Rhijn CM, Litvinov SV. Expression of Ep-CAM in normal, regenerating, metaplastic, and neoplastic liver. J. Pathol. 1999; 188; 201-206.
28. Schmelzer E, Reid LM. EpCAM expression in normal, non-pathological tissues. Front. Biosci. 2008; 13; 3096-3100.
29. Govaere O, Komuta M, Berkers J et al. Keratin 19: a key role player in the invasion of human hepatocellular carcinomas. Gut in press. doi: 10.1136/gutjnl-2012-304351.